MBNL1 and neoplasm: CCK-8 showed that the cell viability of NSCLC CSCs decreased significantly after treatment with an overexpression of lncRNA MBNL1-AS1 (Fig. 3f), along with a significantly decreased 50% inhibition concentration (IC50) value of gefitinib and cisplatin in cells treated with oe-lncRNA MBNL1-AS1 (Fig. 3g), suggesting that lncRNA MBNL1-AS1 overexpression increased the sensitivity of A549 CSCs to anti-tumor drugs.